arrow
J

John E. Godwin

chiles research institute
H指数:35
被引数:6,476

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

lisocabtagene maraleucel用于不适合HSCT的R/R LBCL患者的治疗:PILOT研究2期最终结果

2025-05-050
OA
Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

NPM1突变急性髓系白血病中ELN2022风险分层的评估:一项来自Fred Hutch和SWOG的研究

BLOOD
IF23.1
2024-11-050
PRE
Liver X receptor activation in chronic myelogenous leukemia cells yields distinct mass fingerprints by whole cell MALDI-TOF MS, which correspond to changes in cell viability, gene expression, and differentiation markers
2024-06-010
OAAI
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
2020-10-15103
OAAI
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report
2020-08-1227
OAAI
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma
2020-02-2959
OAAI